Response by Hänggi and Macdonald to Letter Regarding Article, “Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])”

DOI: 10.1161/STROKEAHA.117.016603

Issn Print: 0039-2499

Publication Date: 2017/04/01

Daniel Hänggi; R. Loch Macdonald


		Checking for direct PDF access through Ovid

Abstract unavailable for this article.


		Loading Related Articles